Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S5-S11 , March 2004

Update on the mechanism of action of bimatoprost: a review and discussion of new evidence

  • Achim H.-P. Krauss, PhD
    • ,
  • David F. Woodward, PhD

      Affiliations

    • Corresponding Author InformationReprint address: David F. Woodward, PhD, Biological Sciences RO-2C, Allergan Inc., 2525 Dupont Drive, Irvine, CA 92612-1531.

References 

  1. Bárány EH. Simultaneous measurement of changing intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion. Invest Ophthal. 1964;3:135–143
  2. Basu S, Sjöquist B, Stjernschantz J, Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids. 1994;50:161–168
  3. Bill A. Conventional and uveo-scleral drainage of aqueous humour in the Cynomolgus Monkey (macaca irus) at normal and high intraocular pressures. Exp Eye Res. 1966;5:45–54
  4. Brubaker RF, Schoff EO, Nau CB, et al.  Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131:19–24
  5. Cantor LB. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Exp Opin Invest Drugs. 2001;10:721–731
  6. Davies SS, Ju W-K, Neufeld AH, et al.  Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocular Pharmacol Ther. 2003;19:45–54
  7. Dubiner H, Cooke D, Dirks M, et al.  Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30 day comparison with the latanoprost. Surv Ophthalmol. 2001;45:S353–S360
  8. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47(Suppl 1):S105–S115
  9. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110:609–614
  10. Hellberg MR, McLaughlin MA, Sharif NA, et al.  Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S13–S33
  11. Hellberg MR, Sallee VL, McLaughlin MA. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17:421–432
  12. Hellberg MR, Ke T-L, Haggard K, et al.  The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2a by human and rabbit ocular tissue. J Ocular Pharmacol Ther. 2003;19:97–103
  13. Higginbotham EJ, Schuman JS, Goldberg I, et al.  One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286–1293
  14. Ke TL, Graff G, Spellman JM, et al.  Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: (II. In vitro bioactivation and permeation of external ocular barriers). Inflammation. 2000;24:371–384
  15. Kelly CR, Williams GW, Sharif NA. Real-time intracellular calcium mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J Pharmcol Exp Ther. 2003;304:238–245
  16. Kozak KR, Crews BC, Morrow JD, et al.  Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol ester and ethanolamides. J Biol Chem. 2002;277:44877–44885
  17. Kozak KR, Crews BC, Ray JL, et al.  Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem. 2001;276:36993–36998
  18. Laibovitz RA, Vandenburgh AM, Felix C, et al.  Comparison of the ocular hypotensive lipid AGN 192024 with timolol. Dosing, efficacy and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001;119:994–1000
  19. Liang Y, Li C, Guzman VM, et al.  Comparison of prostaglandin F2α, bimatoprost (prostamide) and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem. 2003;278:27267–27277
  20. Matsuda S, Kanemitsu N, Nakamura A. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp Eye Res. 1997;64:707–711
  21. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S34–S40
  22. Noecker RS, Dirks MS, Choplin NT, et al.  A six-month randomized clinical trial comparing the intraocular pressure lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63
  23. Parrish RK, Palmberg P, Sheu W-P, for the XLT study group . A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked evaluation multicenter study. Am J Ophthalmol. 2003;135:688–703
  24. Pate DW, Jarvinen K, Urtti A, et al.  Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr Eye Res. 1995;14:791–797
  25. Richter M, Krauss AH-P, Woodward DF, et al.  Morphological changes in the anterior eye segment after long term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44:4419–4426
  26. Ross RA, Craib SJ, Stevenson LA, et al.  Pharmacological characterization of the anandamide cyclooxygenase metabolite; prostaglandin E2 ethanolamide. J Pharmacol Exp Ther. 2002;301:900–907
  27. Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002;18:313–324
  28. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003;44:715–721
  29. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 2001;432:211–213
  30. Sherwood M, Brandt J, et al.  Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(Suppl 4):S361–S368
  31. Sjöquist B, Basu S, Byding P, et al.  The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Dispos. 1998;26:745–754
  32. Sjöquist B, Johansson A, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Arzneimittelforschung/Drug Res. 1999;49:240–249
  33. Sjöquist B, Stjernschantz J. Ocular and systemic pharma cokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(Suppl 1):S6–S12
  34. Sjöquist B, Tajallaei S, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye. Arzneimittelforschung/Drug Res. 1999;49:225–233
  35. Sjöquist B, Uhlin A, Byding P, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye. Arzneimittelforschung/Drug Res. 1999;49:234–239
  36. Toris CB, Yablonski ME, Wang Y, et al.  Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 1995;61:649–657
  37. Williams RD. Efficacy in bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther. 2002;19:275–281
  38. Woodward DF, Krauss AH, Chen J, et al.  The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S337–S345
  39. Woodward DF, Krauss AH, Chen J, et al.  Pharmacological characterization of a novel anti-glaucoma agent. J Pharmacol Exp Ther. 2003;305:772–785

☆ Drs. Krauss and Woodward are employees of Allergan, Inc.

PII: S0039-6257(03)00189-9

doi: 10.1016/j.survophthal.2003.12.014

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S5-S11 , March 2004

Article Tools

* Image Usage & Resolution